Protein / target

Synaptophysin

Encoded bySYPP08247Homo sapiensSwiss-Prot

UniProt: P08247 Ensembl: ENSG00000102003 HGNC: HGNC:11506 NCBI Gene: 6855

Antibody-tractable

Druggability

UniProt SigP or TMHMM

Research papers

Protein at a glance

Biological role

Identical protein binding

Strongest disease association

Genetic Diseases, Inborn

Via encoding gene SYP · Genetic evidence · score 0.31

Research activity

Emerging research

3 papers · latest 2024

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Possibly involved in structural functions as organizing other membrane components or in targeting the vesicles to the plasma membrane.

View complete UniProt function annotation

Possibly involved in structural functions as organizing other membrane components or in targeting the vesicles to the plasma membrane. Involved in the regulation of short-term and long-term synaptic plasticity (By similarity)

Subcellular location

Cytoplasmic vesicle, secretory vesicle, synaptic vesicle membraneSynapse, synaptosome

Domains and Gene Ontology detail (22)

Domains & features

MARVEL

Gene Ontology

Cexcitatory synapse
Cneuromuscular junction
Cneuron projection
Cperinuclear region of cytoplasm
Cpresynaptic active zone
Cpresynaptic membrane
CSchaffer collateral - CA1 synapse
Csynaptic vesicle
Csynaptic vesicle membrane
Cterminal bouton
Fcholesterol binding
Fidentical protein binding

313 aa · 34 kDa · 2 isoforms

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene SYP

Gene-level evidence surfaced through the gene SYPthat encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Genetic Diseases, Inborn

0.31Limited support

Genetic evidence dominant · Open Targets 0.19

Neurodegenerative Diseases

0.27Preliminary

Pathway evidence dominant · Open Targets 0.38 · no direct causal or clinical evidence

Neoplasms

0.14Preliminary

Literature evidence dominant · Open Targets 0.11 · no direct causal or clinical evidence

Alzheimer's Disease

0.11Preliminary

Literature evidence dominant · Open Targets 0.09 · no direct causal or clinical evidence

Adenocarcinoma

0.11Preliminary

Literature evidence dominant · Open Targets 0.09 · no direct causal or clinical evidence

View evidence synthesis (5)

Genetic Diseases, InbornLimited support

0.31

agreement 0.19–0.43

Genetic100%

Open Targets aggregate 0.19 · 1 independent evidence family

Neurodegenerative DiseasesPreliminary

0.27

agreement 0.09–0.44

Pathway89%Literature11%

Open Targets aggregate 0.38 · 2 independent evidence families · no direct causal or clinical evidence

NeoplasmsPreliminary

0.14

agreement 0.00–0.41

Literature100%

Open Targets aggregate 0.11 · 1 independent evidence family · no direct causal or clinical evidence

Alzheimer's DiseasePreliminary

0.11

agreement 0.00–0.38

Literature100%

Open Targets aggregate 0.09 · 1 independent evidence family · no direct causal or clinical evidence

AdenocarcinomaPreliminary

0.11

agreement 0.00–0.38

Literature100%

Open Targets aggregate 0.09 · 1 independent evidence family · no direct causal or clinical evidence

This ranking differs from Open Targets' own: re-weighting moves genetically-evidenced diseases above more heavily co-mentioned ones. The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations

Neurodegenerative Diseases0.38

Genetic Diseases, Inborn0.19

Neoplasms0.11

Alzheimer's Disease0.09

Adenocarcinoma0.09

Breast Neoplasms0.08

Schizophrenia0.08

Tractability

Antibodies — Emerging

Feasibility evidence (uniprot sigp or tmhmm) — no clinical-stage drug of this modality recorded.

Protein degraders — Emerging